Expert Interview
A Second Look: Discussing Replimune's RP1 (vusolimogene oderparepvec) in Combination with Nivolumab for Advanced Melanoma Ahead of its April FDA PDUFA Date
Ticker(s): REPL, MRK, BMY, NVS, RHHBY, PFE, IOVAInstitution: UT Southwestern
- Professor of Medicine, Pathology at UTSW
- Manages 100+ CML and 50+ melanoma patients
- Research interests include molecular pathogenesis of lymphoma and leukemia, tumor immunology and GVHD
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
